Intensity Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Intensity Therapeutics, Inc. carries a market capitalization of 8.30M, placing it among publicly traded companies globally. Its enterprise value stands at -322,715.96, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.30M |
| Enterprise Value | -322,715.96 |
Share Statistics
Intensity Therapeutics, Inc. currently has 2.54M shares outstanding.
| Shares Outstanding | 2.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.12 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | -1.08 |
| P/OCF Ratio | -1.08 |
Financial Position
Intensity Therapeutics, Inc. maintains a current ratio of 4.86, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.86 |
| Quick Ratio | 4.57 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -139.27 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Intensity Therapeutics, Inc.'s stock has declined approximately -44.72362% over the past 52 weeks. The 50-day moving average sits at 4.39, while the 200-day moving average is 7.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.72362% |
| 50-Day Moving Average | 4.39 |
| 200-Day Moving Average | 7.50 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.10M, while operating income came in at -11.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.10M |
| Pretax Income | -10.69M |
| Net Income | -10.69M |
| EBITDA | -11.10M |
| EBIT | -11.10M |
| Earnings Per Share (EPS) | -6.40 |
Balance Sheet
Intensity Therapeutics, Inc. holds 10.25M in cash and equivalents against 102,000.00 in total debt, resulting in a net debt position of -10.24M. Total book value stands at -80.82M, with working capital of 8.66M providing operational flexibility.
| Cash & Cash Equivalents | 10.25M |
| Total Debt | 102,000.00 |
| Net Debt | -10.24M |
| Equity (Book Value) | -80.82M |
| Book Value Per Share | -48.39 |
| Working Capital | 8.66M |
Cash Flow
Intensity Therapeutics, Inc. produced -9.07M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.07M |
| Capital Expenditures | N/A |
| Free Cash Flow | -9.07M |
| FCF Per Share | -5.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -187.22 |
| FCF Yield | -92.36 |
Stock Splits
Intensity Therapeutics, Inc.'s most recent stock split took place on February 19, 2026 with a 25:1 split ratio.
| Last Split Date | 2/19/2026 |
| Split Ratio | 25:1 |
Scores
Intensity Therapeutics, Inc. posts an Altman Z-Score of -8.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.79 |